GrahamB wrote: By my count, the poster David Rosenberg has posted the same video showing a mouse that has EAE and making or inferring claims regarding FSDs new, new drug candidate.
There is a recurrent question posted here regarding the posters relationship to FSD, that appears to remain unanswered. He states he is a shareholder only, yet has hosted video interviews with FSD management, apparently leads a number of social media boards promoting the company, and has posted tht he has been offered compensation for such promotional activities.
Importantly, no disclosures have been made regarding this suspicious activity, and denials of any direct association or financial ties , beyond being a shareholder, with the company by this poster have been made publically.
Regardless of his association, the recurrent posting of the same material, in my view, is distasteful at best, and highly promotional and misleading at worst.
Viewed in the context of current regulatory statements from the OSC and concerns raised by board members about a direct relationship of this poster with FSD,in my opinion. all readers should note the potential for abuse of said notice, and IMO the suspicious nature of such postings.
What do followers of this company think?
Are my thoughts here reasonable?
Is this recurrrent posting of the same promotional material concerning and appropriate even if there is no association with this poster and the company?
Willl not be here as much anymore, as I do find the postings distasteful, and will vote with my feet , so to speak. I have enjoyed the oppportunity to share and discusss insights regarding financial data,but this pure speculative and in my view unsubstantiated promotion is un enjoyable. Will pop in from time to time, and extend positive wishes to all, and a belated happy new year.
best regards,
G
These thoughts are my opinion, and do not constitute financial advice, nor recommendations to buy or sell this security.
"We are issuing this notice to illustrate some of the specific problems we are seeing and reinforcing our commitment to ensuring that promotional activity by, or on behalf of, issuers remains balanced and not misleading. Although our examples specifically relate to activity we are seeing in the venture issuer marketplace, our expectations regarding disclosure and promotional activities apply to all issuers.
III. Activities of concern
The following are examples of promotional activities that may potentially be misleading:
CSA Staff Notice 51-356
Problematic promotional activities by issuers
1
We will also be undertaking a separate project to analyze the impact of activist short sellers on the Canadian capital markets.
• disseminating presentations, marketing materials, social media posts, or other information that describe early- stage plans with unwarranted certainty, or make unsupported assertions about growth of markets or demand for a product;
• issuing numerous news releases that disclose no new material facts;
• compensating third parties, who use social media and general investing blogs to promote issuers, but do not
disclose their agency, compensation and/or financial interest;
• announcing an issuer name and/or business change to reference an emerging industry or technology such as block chain, cannabis, battery minerals, or cryptocurrency without a supporting business plan or comprehensive risk disclosure;
• announcing a positive event such as a large acquisition
https://www.osc.ca/sites/default/files/pdfs/irps/csa_20181129_51-356_problematic-promotional-activities-issuers.pdf
https://www.osc.ca/sites/default/files/pdfs/irps/csa_20181129_51-356_problematic-promotional-activities-issuers.pdf